Clinical Trial Update: A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C [Phase 2]

View source ↗

Summary

A Phase 2 study of setrobuvir in combination with peginterferon alfa-2a and ribavirin for genotype 1 chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• Setrobuvir (setrobuvir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED